Mark Frohlich, Indapta Therapeutics CEO
Cell therapy pioneer Mark Frohlich takes the helm at tiny Indapta as a suite of big-name backers jump aboard
Off-the-shelf cell therapy has become a red-hot field of investment in recent years as the first rounds of human data start rolling out. Now, cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
